Pearson O H, Hubay C A, Gordon N H, Marshall J S, Crowe J P, Arafah B M, McGuire W
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Cancer. 1989 Nov 1;64(9):1819-23. doi: 10.1002/1097-0142(19891101)64:9<1819::aid-cncr2820640910>3.0.co;2-n.
Postmenopausal women who underwent modified radical mastectomy for Stage II, estrogen receptor (ER)-positive breast cancer were randomized to receive endocrine treatment (tamoxifen [T], 40 mg daily for 3 years) alone versus endocrine treatment plus five-drug chemotherapy (Cytoxan [cyclophosphamide, C], methotrexate [M], 5-fluorouracil [F], vincristine [V], and prednisone [P], CMFVP, for 1 year). Chemotherapy consisted of oral P (1 month), oral C (12 months), and intravenous MFV weekly for the first 3 months, biweekly for 3 months, and triweekly for 6 months. Patients were entered into the study from October 1979, to October 1985, and the median follow-up is 55 months. Results show that with 94 postmenopausal women, disease-free survival (DFS) is significantly greater (P = 0.04, log-rank test; P = 0.03, multivariate analysis) in patients receiving CMFVPT as compared to those receiving T alone. These results suggest that intensive chemotherapy combined with T is more effective in delaying recurrence than T alone in postmenopausal patients.
因II期雌激素受体（ER）阳性乳腺癌接受改良根治性乳房切除术的绝经后女性被随机分为两组，一组单独接受内分泌治疗（他莫昔芬[T]，每日40毫克，持续3年），另一组接受内分泌治疗加五药联合化疗（环磷酰胺[C]、甲氨蝶呤[M]、5-氟尿嘧啶[F]、长春新碱[V]和泼尼松[P]，即CMFVP方案，持续1年）。化疗方案包括口服P（1个月）、口服C（12个月），以及静脉注射MFV，前3个月每周1次，接下来3个月每2周1次，最后6个月每3周1次。患者于1979年10月至1985年10月纳入本研究，中位随访时间为55个月。结果显示，94名绝经后女性中，接受CMFVPT方案的患者无病生存期（DFS）显著长于单独接受T治疗的患者（对数秩检验P = 0.04；多变量分析P = 0.03）。这些结果表明，在绝经后患者中，强化化疗联合T治疗在延迟复发方面比单独使用T更有效。
